Conferences - Results from #7140

ASCO GU 2019: Long-term Outcomes of Hypoxia Modification in Bladder Preservation: Update from BCON Trial February 15, 2019

ASCO GU 2019: A Randomized Trial Comparing Fluorocholine-PET/CT with Conventional Imaging in Prostate Cancer February 15, 2019

ASCO GU 2019: Discussion on: The ARAMIS Trial, the Final Analysis of LATITUDE Study, and the ARCHES Trial February 15, 2019

ASCO GU 2019: Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-Resistant Prostate Cancer February 15, 2019

ASCO GU 2019: ARCHES Trial-Phase 3 Study of ADT with Enzalutamide in mHSPC February 15, 2019

ASCO GU 2019: Keynote-365: Pembrolizumab Plus Olaparib in Docetaxel Pretreated Patients with Metastatic Castrate-resistant Prostate Cancer February 15, 2019

ASCO GU 2019: Final Analysis of LATITUDE, A Phase III in Patients with Newly Diagnosed High-risk Metastatic Castration-naïve Prostate Cancer February 15, 2019

ASCO GU 2019: Skeletal Related Events in CTRIAL-IE 13-21: Radium-223 in Combination with Enzalutamide for Patients with mCRPC February 15, 2019

ASCO GU 2019: Phase II Study of Niraparib in Patients with Metastatic Castration-Resistant Prostate Cancer and Biallelic DNA-Repair Gene Defects : Preliminary Results of GALAHAD February 15, 2019

ASCO GU 2019: Updated Analysis of Progression-Free Survival with First Subsequent Therapy and Safety in the SPARTAN Study of Apalutamide in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer February 15, 2019

ASCO GU 2019: A Multicentric Phase II Randomized Trial of Docetaxel plus Enzalutamide versus Docetaxel as First Line Chemotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer: CHEIRON Study February 15, 2019

ASCO GU 2019: Intensification Versus Deintensification in High-Risk Prostate Cancer February 15, 2019

ASCO GU 2019: A Phase III Trial of Docetaxel versus Docetaxel and Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer: DORA February 15, 2019

ASCO GU 2019: Cost-Effectiveness of Metastasis-Directed Therapy in the Setting of Oligometastatic Hormone-Sensitive Prostate Cancer February 15, 2019

ASCO GU 2019: Quality of Life-Focused Decision-Making for Castrate-Sensitive Prostate Cancer February 15, 2019

ARAMIS: Efficacy and Safety of Darolutamide in nmCRPC | ASCO GU 2019 February 15, 2019

ASCO GU 2019: Discussion on: Results of Checkmate 650 and Circulating Tumor Cell Number as a Transitional Surrogate Endpoint for Survival in mCRPC Trials February 15, 2019

ASCO GU 2019: Initial Results from Checkmate 650, a Phase II Study of Nivolumab Plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer February 15, 2019

ASCO GU 2019: Assessment of Circulating Tumor Cell Number as a Transitional Surrogate Endpoint for Survival in Phase II Trials for Metastatic Castrate-Resistant Prostate Cancer February 15, 2019

ASCO GU 2019: Hypocalcemia in Patients with Castration-Resistant Prostate Cancer Treated with Denosumab: The REDUSE Trial February 14, 2019

Page 358 of 616